Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?

view original post

The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there’s still plenty of risk here.

An S&P 500 shakeup is due soon. These stocks could join the index

The Cloud Computing Market Could Surge by 218%: Buy This ETF That Holds a Big Position in Alphabet

Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.

Enter Your Email Address

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Opt-out any time, we hate spam!